Peptide Research News - Esperance Pharmaceuticals Presents Results From Phase 1 Study of EP-100 in ... - PipelineReview.com (press release)

Esperance Pharmaceuticals Presents Results From Phase 1 Study of EP-100 in ... - PipelineReview.com (press release)

Esperance Pharmaceuticals Presents Results From Phase 1 Study of EP-100 in ... PipelineReview.com (press release) BATON ROUGE, LA, USA I June 4, 2012 I Esperance Pharmaceuticals presented its Phase 1 study of EP-100, a novel targeted membrane‐disrupting peptide (tMDP) in advanced solid tumors at the American Society for Clinical Oncology (ASCO) Annual Meeting in ... and more »

Click Here to read the entire article...